Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
Zachary A. Hing(The Ohio State University), Rosa Lapalombella(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Shaneice Mitchell(Stanford University), Virginia M. Goettl(The Ohio State University), Katie Williams(The Ohio State University), Qingxiang Sun(University of Electronic Science and Technology of China), Sharon Shacham(Roche (Switzerland)), Yuh Min Chook(The University of Texas Southwestern Medical Center), Ramiro Garzon(Unknown), Erkan Baloglu(ProterixBio (United States)), Tülin Çağatay(The University of Texas Southwestern Medical Center), Jared C. Smith(The Ohio State University), Ho Yee Joyce Fung(Southwestern Medical Center), Dalia El‐Gamal(University of Nebraska Medical Center), Xueyan Yu(Shaanxi Provincial People's Hospital), Xia Meng(Wuhan University), David Lucas(Vital Strategies), Amy M. Lehman(The Ohio State University), John C. Byrd(University of Cincinnati), Michael Kauffman(Roche (Switzerland)), Punithavathi Ranganathan(The Ohio State University)
Cited by 144
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890